Regenxbio
RGNX
85 hedge funds and large institutions have $401M invested in Regenxbio in 2017 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 33 increasing their positions, 21 reducing their positions, and 9 closing their positions.
133% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 9
57% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 21
18% more capital invested
Capital invested by funds: $339M → $401M (+$61.9M)
9% more funds holding
Funds holding: 78 → 85 (+7)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.5% less ownership
Funds ownership: 69.11% → 68.61% (-0.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$45.8M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$24.5M |
| 3 |
RI
RTW Investments
New York
|
+$18.8M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$9.31M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$5.78M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
-$11.6M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$6.58M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
-$6.53M |
| 4 |
Jennison Associates
New York
|
-$5.42M |
| 5 |
NCM
Numina Capital Management
New York
|
-$3.44M |
RGNX Hedge Fund Activity: Q1 2017 in Review
85 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Regenxbio (RGNX) for Q1 2017, worth a combined $401M — up 18% from $339M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new RGNX positions and 9 closed out — a net gain of 12 holders — while 33 added to existing stakes and 21 trimmed.
The largest buyer was BlackRock, adding an estimated $45.8M. The largest seller was Bain Capital Public Equity Management, cutting an estimated $11.6M.
- 85 institutional investors held Regenxbio (RGNX) as of Q1 2017, up from 78 in Q4 2016.
- Funds reported $401M of Regenxbio stock for Q1 2017, up 18% quarter-over-quarter.
- 21 funds opened new Regenxbio positions in Q1 2017 and 9 closed out, a net change of +12 holders.
- The largest Regenxbio buyer in Q1 2017 was BlackRock, an estimated $45.8M added.
- The largest Regenxbio seller in Q1 2017 was Bain Capital Public Equity Management, an estimated $11.6M sold.
Based on aggregated 13F filings for Q1 2017.